The safety of probiotics

被引:207
作者
Snydman, David R. [1 ,2 ,3 ]
机构
[1] Tufts Univ New England Med Ctr, Div Geog Med & Infect Dis, Boston, MA 02111 USA
[2] Tufts Univ New England Med Ctr, Dept Med, Boston, MA 02111 USA
[3] Tufts Univ, Sch Med, Boston, MA 02111 USA
关键词
D O I
10.1086/523331
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Probiotics are generally defined as microorganisms that, when consumed, generally confer a health benefit on humans. There is considerable interest in probiotics for a variety of medical conditions, and millions of people around the world consume probiotics daily for perceived health benefits. Lactobacilli, bifidobacteria, and lactococci have generally been regarded as safe. There are 3 theoretical concerns regarding the safety of probiotics: (1) the occurrence of disease, such as bacteremia or endocarditis; (2) toxic or metabolic effects on the gastrointestinal tract; and (3) the transfer of antibiotic resistance in the gastrointestinal flora. In this review, the evidence for safety of the use of or the study of probiotics is examined. Although there are rare cases of bacteremia or fungemia related to the use of probiotics, epidemiologic evidence suggests no population increase in risk on the basis of usage data. There have been many controlled clinical trials on the use of probiotics that demonstrate safe use. The use of probiotics in clinical trials should be accompanied by the use of a data-safety monitoring board and by knowledge of the antimicrobial susceptibilities of the organism used.
引用
收藏
页码:S104 / S111
页数:8
相关论文
共 110 条
[1]
MOBILIZATION AND LOCATION OF THE GENETIC DETERMINANT OF CHLORAMPHENICOL RESISTANCE FROM LACTOBACILLUS-PLANTARUM CATC2R [J].
AHN, C ;
COLLINSTHOMPSON, D ;
DUNCAN, C ;
STILES, ME .
PLASMID, 1992, 27 (03) :169-176
[2]
Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections:: A randomized study [J].
Arvola, T ;
Laiho, K ;
Torkkeli, S ;
Mykkänen, H ;
Salminen, S ;
Maunula, L ;
Isolauri, E .
PEDIATRICS, 1999, 104 (05) :art. no.-e64
[3]
Increased enterocyte production in gnotobiotic rats mono-associated with Lactobacillus rhamnosus GG [J].
Banasaz, M ;
Norin, E ;
Holma, R ;
Midtvedt, T .
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2002, 68 (06) :3031-3034
[5]
Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii [J].
Bassetti, S ;
Frei, R ;
Zimmerli, W .
AMERICAN JOURNAL OF MEDICINE, 1998, 105 (01) :71-72
[6]
BERG RD, 1980, INFECT IMMUN, V29, P1073
[7]
TREATMENT OF RECURRENT CLOSTRIDIUM-DIFFICILE COLITIS WITH LACTOBACILLUS GG [J].
BILLER, JA ;
KATZ, AJ ;
FLORES, AF ;
BUIE, TM ;
GORBACH, SL .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1995, 21 (02) :224-226
[8]
Lactobacilli and acidosis in children with short small bowel [J].
Bongaerts, G ;
Bakkeren, J ;
Severijnen, R ;
Sperl, W ;
Willems, H ;
Naber, T ;
Wevers, R ;
van Meurs, A ;
Tolboom, J .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2000, 30 (03) :288-293
[9]
A randomized, double-blind trial of lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease [J].
Bousvaros, A ;
Guandalini, S ;
Baldassano, RN ;
Botelho, C ;
Evans, J ;
Ferry, GD ;
Goldin, B ;
Hartigan, L ;
Kugathasan, S ;
Levy, J ;
Murray, KE ;
Oliva-Hemker, M ;
Rosh, JR ;
Tolia, V ;
Zholudev, A ;
Vanderhoof, JA ;
Hibberd, PL .
INFLAMMATORY BOWEL DISEASES, 2005, 11 (09) :833-839
[10]
Probiotic use in clinical practice: what are the risks? [J].
Boyle, Robert J. ;
Robins-Browne, Roy M. ;
Tang, Mimi L. K. .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2006, 83 (06) :1256-1264